Nuclear imaging is more sensitive for the detection of viable myocardium than dobutamine echocardiography

Nuclear Medicine Communications

Volumn 24, Issue 4, 2003, Pages 375-381

  Sloof, G W ^a   Knapp, F F ^a   van LINGEN, A ^a   Eersels, J ^b   Poldermans, D ^b   Bax, J J ^b  

^a OAK RIDGE NATIONAL LABORATORY   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

BMIPP; Dobutamine; Echocardiography; FDG; Myocardial viability; Perfusion

Indexed keywords

DIAGNOSTIC AGENT; DOBUTAMINE; FATTY ACID; FLUORODEOXYGLUCOSE F 18; GLUCOSE; IODOBENZENE; IODOFILTIC ACID; RADIOPHARMACEUTICAL AGENT; THALLIUM; THALLIUM CHLORIDE;

ARTICLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING ORGAN SYSTEMS; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; ECHOCARDIOGRAPHY; ECHOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE; HUMAN; METABOLISM; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CORONARY ARTERIOSCLEROSIS; DOBUTAMINE; ECHOCARDIOGRAPHY; FATTY ACIDS; FLUORODEOXYGLUCOSE F18; GLUCOSE; HEART VENTRICLES; HUMANS; IODOBENZENES; MIDDLE AGED; MYOCARDIUM; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THALLIUM; TISSUE SURVIVAL; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0347794776     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200304000-00006     Document Type: Article

References (23)

1. Rahimtoola SH. The hibernating myocardium. Am Heart J 1989; 117: 211-221.
2. Dilsizian V, Bonow RO. Current diagnostic techniques of assessing myocardial viability in hibernating and stunned myocardium. Circulation 1993; 87: 1-20.
3. Bonow RO. Identification of viable myocardium. Circulation 1996; 94: 2674-2680.
4. Rahitmoola SH. Importance of diagnosing hibernating myocardium: how and in whom? J Am Coll Cardiol 1997; 30: 1701-1706.
5. Vanoverschelde JLJ, Wijns W, Borgers M, et al. Chronic myocardial hybernation in humans: from bedside to bench. Circulation 1997; 95: 1961-1971.
6. Bax JJ, Wijns W, Cornel JH, Visser FC, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: Comparison of pooled data. J Am Coll Cardiol 1997; 30: 1451-1460.
7. 99Tc-sestamibi. Circulation 1994; 89: 2552-2561.
8. Knapp Jr FF, Franken P, Kropp J. Cardiac SPECT with iodine-123-labeled fatty acids: evaluation of myocardial viability with BMIPP. J Nucl Med 1995; 36: 1022-1030.
9. Sloof GW, Visser FC, Bax JJ, et al. Increased uptake of iodine-123-BMIPP in chronic ischemic heart disease: comparison with fluorine-18-FDG SPECT. J Nucl Med 1998; 39: 255-260.
10. Bax JJ, Cornel JH, Visser FC, et al. Prediction of recovery of myocardial dysfunction following revascularization: comparison of fluorine-18-fluorodeoxyglucose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography. J Am Coll Cardiol 1996; 28: 558-564.
11. 123I radioiodination of 15(p-I-phenyl)-9-methyl pentadecanoic acid, a potential myocardial tracer. Eur J Nucl Med 1987; 13: 159-160.
12. Knuuti MJ, Yki-Järvinen H, Voipio-Pulkki LM, et al. Enhancement of myocardial [F-18]-FDG uptake by a nicotinic acid derivate. J Nucl Med 1994; 35: 989-998.
13. Van Lingen A, Huijgens PC, Visser FC, et al. Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma camera. Eur J Nucl Med 1992; 19: 315-321.
14. Schiller NB, Shah PM, Crawford M, et al. Recommendation for quantification of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 358-367.
15. Maes A, Flameng W, Nuyts J, et al. Histological alterations in chronically hypoperfused myocardium; correlation with PET findings. Circulation 1994; 90: 735-745.
16. Depré C, Vanoverschelde J-LJ, Melin JA, et al. Structural and metabolic correlates of the reversibility of chronic left ventricular ischemic dysfunction in humans. Am J Physiol 1995; 268: H1265-H1275.
17. Shivalkar B, Maes A, Borgers M, et al. Only hibernating myocardium invariably shows early recovery after coronary revascularization. Circulation 1996; 94: 308-315.
18. Baumgartner H, Forenta G, Lau YK, et al. Assessment of myocardial viability by dobutamine echocardiography, positron emission tomography and thallium-201 SPECT. Correlation with histopathology in explanted hearts. J Am Coll Cardiol 1998; 32: 1701-1708.
19. Sun KT, Czernin J, Krivokapich J, et al. Effects of dobutamine stimulation on myocardial blood flow, glucose metabolism, and wall motion in normal and dysfunctional myocardium. Circulation 1996; 94: 3146-3154.
20. Sawada S, Elsner G, Segar DS, et al. Evaluation of patterns of perfusion and metabolism in dobutamine-responsive myocardium. J Am Coll Cardiol 1997; 29: 55-61.
21. Melon PG, De Landsheere CM, Degueldre C, Peters JL, Kulbertus HE, Pierard LA. Relation between contractile reserve and positron emission tomographic patterns of perfusion and glucose utilization in chronic ischemic left ventricular dysfunction. Implications for identification of myocardial viability. J Am Coll Cardiol 1997; 30: 1651-1659.
22. Cornel JH, Bax JJ, Elhendy A, et al. Agreement and disagreement between ‘metabolic viability’ and ‘contractile reserve’ in akinetic myocardium. J Nucl Cardiol 1999; 6: 383-388.
23. Bax JJ, Visser FC, Elhendy A, et al. Prediction of improvement of regional left ventricular function after revascularization using different perfusion-metabolism criteria. J Nucl Med 1999; 40: 1866-1873.